Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

The Obesity Gurukul initiative will train over 20,000 healthcare professionals across India through a hybrid education model ...

"Obesity is a complex, chronic condition that requires more than just treatment--it demands continuous medical education, empathy, and coordinated action across the healthcare ecosystem," said Dr.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.